Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab adjunctive therapy in severe eosinophilic asthma: 24-week randomized placebo-controlled trial
2014-002513-27Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Mepolizumab arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in St. George’s Respiratory Questionnaire total score. Started Sep 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2014-002513-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002513-27.